Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PDA Block 3 > Antivirals > Flashcards

Antivirals Flashcards

1
Q

Virus Replication (General steps)

A
  1. Adsorption
  2. Penetration
  3. Uncoating
  4. Transcription
  5. Translation
  6. Synthesis of virus nucleic acid and production of virus proteins
  7. Assembly of new virus particles
  8. Egress
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Problems with antiviral therapy

A
  • Viruses take over cell’s synthetic machinery for their own reproduction
  • Viral latency
  • Intracellular stages afford protection from certain arms of immune system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

When do clinical symptoms first appear and what is the significance of this in terms of drug administration?

A

Viral replication peaks near the time clinical symptoms first appear

  • Drugs most effective if administered before the onset of symptoms
  • NOT TRUE for Herpesvirus, HIV, or hepatitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Therapy does not eliminate _____ forms of viruses

Viral eradication requires a competent ______ _______ ______

A

Latent; host immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the difference between active and passive immunization?

A

Active - Vaccination

Passive - Injection of immune globulin antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Drugs that can interfere with viral adsorption/penetration

Influenza A prophylaxis/treatment:

Influenza A and B treatment/prophylaxis:

A

Influenza A prophylaxis/treatment: Amantadine

Influenza A and B treatment/prophylaxis: Oseltamivir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Amantadine

Virus:

Mechanism Of Action:

Timing of administration:

A

Virus: Influenza A, NOT influenza B

Mechanism Of Action: Blocks viral uncoating with influenza A M2 protein (an ion channel)

Timing of administration: Reduces fever in 50% of patients and illness duration by 1-2 days if given within 2 days of illness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Amantadine side effects

A

CNS effects

  • Slurred speech, anxiety
  • Confusion depression
  • Headache, hallucinations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Oseltamivir

Mechanism:

Uses:

Timing of administration:

A

Mechanism: Prodrug converted to oseltamivir carboxylate - Competitiively inhibits influenza neuraminidases (interferes with viral release and viral penetration)

Uses: Uncomplicated influenza A and B in patients > 1 year old

Timing of administration: Only effective if given within 48 hours of symptom onset (oral administration - 5 day regimen)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Side effects of Oseltamivir

A
  • Nausea, vomiting Diarrhea
  • Bronchitis (cough)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  • As of 2008/2009, Influenza A (H3N2) was 100% resistant to ________
  • As of 2008/2009, Influenza A (H1N1) was 99% resistant to ________
A

Amantadine; Oseltamivir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Now we mostly use Oseltamivir and zanamivir for influenza due to _______ ________

A

Amantadine resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Inhibition of Nucleic Acid Synthesis

A
  • Most viruses encode at least one enzyme involved in replication of viral nucleic acid
  • A preponderance of drugs for herpes family
    • Encodes several of its own enzymes, incl:
      • Thymidine kinase
      • DNA polymerase
      • ribonucleotide reductase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Trifluridine

Mechanism of Action:

Administration:

Use:

Side Effects:

A

Mechanism of Action: Thymidine analog that interferes with DNA synthesis

Administration: Opthalmic use only

Use: Treatment of Herpes simplex types 1 and 2

Side Effects: Burning, stinging, hypersensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Acyclovir Mechanism of Action

A
  • Phosphorylated form is produced 40-100X faster in infected cells
  • Inhibits herpes DNA polymerase 10-30x more effectively than host cell DNA polymerase
  • Competes with deoxy-GTP for DNA polymerase - terminates DNA chain elongation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Acyclovir - Intravenous Uses

A
  • Serious systemic herpes simplex virus (HSV)
  • HSV encephalitis
  • Disseminated neonatal HSV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Acyclovir - Oral Uses

A
  • Primary genital herpes
  • Primary herpetic gingivostomatitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Acyclovir - Topical Uses

A

Primary genital herpes - may shorten healing time when applied early

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Acyclovir - Some Side Effects

A
  • Generally well tolerated
  • Rash-itching
  • Nausea, vomiting, headache, fatigue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Famciclovir

Mechanism of Action:

Uses:

Administration:

A

Mechanism of Action: Prodrug activation (famciclovir → penciclovir → penciclovir-triP) - similar mechanism to acyclovir

Uses: Acute herpes zoster (shingles); treatment and suppression of recurrent genital herpes

Administration: Oral administration (better absorbed than acyclovir)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

_______ (Famiclovir analog) - can reduce genital herpes transmission risk

A

Valacyclovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Side effects of famiciclovir

A

Similar to acyclovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Penciclovir

Mechanism of action:

Use:

Administration:

Side effects:

A

Mechanism of action: similar to acyclovir (not technically a chain terminator due to -OH group)

Use: Recurrent herpes of the lips and face

Administration: Topical

Side effects: Skin irritation, rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

CMV - Cytomegalovirus

A

Latent member of the herpesvirus family

Reactivation occurs in those with compromised immune systems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

CMV in immunocompromised patients

HIV patients:

Solid organ transplants:

A

HIV patients:

  • Most common cause of retinitis and visual loss (80% of CMV disease)
  • Other organs infected include GI, CNS, respiratory

Solid organ transplants:

  • SIngle most common viral infection after solid organ transplantation
  • 20-60% of organ recipients (from organ donor)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Drugs for CMV prophylaxis/infection

A

Ganciclovir

Foscarnet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Ganciclovir

Mechanism of action:

Uses:

Side Effects:

A

Mechanism of action: Similar to acyclovir, except mono-phos. by CMV protein kinase

Uses: CMV retinitis (in AIDS patients); CMV prophylaxis for transplant recipients

Side Effects: Bone marrow suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Foscarnet

Mechanism of Action:

Uses:

A

Mechanism of Action: Selectively inhibits CMV DNA polymerase by binding to its pyrophosphate-binding site; Does not require conversion to triphosphate form to be active

Uses: CMV (cytomegalovirus) retinitis in immunocompromised; Acyclovir-resistant herpes simplex (thymidine kinase mutations)

29
Q

Foscarnet - Side Effects

A
  • Renal damage (30-50%) - reversible
  • Electrolyte imbalances (binds calcium and magnesium)
  • Seizures
  • Compared to ganciclovir, higher % of patients on foscarnet must be taken off due to side effects
30
Q

Do anti-CMV drugs cure the disease?

A

No they can only slow the progression (×̯×)

31
Q

Drugs for Hepatitis and Respiratory syncitial virus

Hepatitis B:

Hepatitis C: (combo)

RSV:

A

Hepatitis B:

  • Lamivudine (3TC)
  • Tenofovir
  • Interferon-α

Hepatitis C:

  • Ribarvirin + Interferon-α + Boceprevir

RSV: Ribavirin

32
Q

Lamivudine (3TC)

Mechanism:

Use:

Administration:

Side Effects:

A

Mechanism: Nucleoside analog phosphorylated by cell enzymes to the active form - inhibits the reverse transcriptase domain of the hepatitis B DNA polymerase

Use: Hepatitis B (Also HIV)

Administration: Oral (85% bioavailable)

Side Effects: Generally well tolerated

  • Nausea; Diarrhea
33
Q

Tenfovir

Mechanism of Action:

Uses:

Administration:

Side Effects:

A

Mechanism of Action: Adenosine monophosphate analog phosphorylated by cell enzymes to the active form - Inhibits the reverse transcriptase domain of the hepatitis B DNA polymerase

Uses: Approved for hepatitis B (also HIV)

Administration: Oral (25% bioavailability)

Side Effects: GI upset

34
Q

Ribavirin mechanism of action

A

Interferes with viral mRNA synthesis by:

  • Mono-P form inhibits inosine-5’-P dehydrogenase and thus GMP (and GTP) synthesis
  • Tri-P form inhibits GTP dependent capping of viral mRNA
35
Q

Uses of Ribavirin

Aerosol use:

Oral use:

A

Aerosol use: Infants and young children with documented severe RSV infections (no longer commonly used)

Oral use: Hepatitis C (in combination with PEG-interferon-α)

36
Q

Ribavirin Side Effects

Aerosol Use:

IV/Oral Use:

A

Aerosol Use: Drug may precipitate in and clog respiratory equipment; pulmonary function deterioration

IV/Oral Use: Anemia, bone marrow suppression

37
Q

Alpha-interferons, recombinant - Approved antiviral uses

A
  • Condyloma acuminata (veneral warts)
  • Hepatitis B and C
  • PEG-alpha-2a and 2b interferons in combination with ribavirin and boceprevir for hepatitis C
38
Q

Interferon-α side effects

A
  • Flu-like syndrome
  • Leukopenia, bone marrow suppression
  • Neurotoxicity, myalgia

Side effects are the greatest limit to long term use

39
Q

Boceprevir

Mechanism of action:

Use:

A

Mechanism of action: Reversible inhibitor of NS3 protease of hepatitis C, blocks formation of infectious virus

Use: Approved for hepatitis C genotype 1; Boceprevir + PEG-interferon-α + ribavirin

40
Q

Most effective treatment for hepatitis C genotype 1

A

3 drug regimen

Ribavirin + PEG-inteferon-α + Boceprevir

41
Q

Boceprevir - side effects

A
  • Anemia, neutropenia
  • Contraindicated with CYP3A substrates or inducers
42
Q

Classes of drugs for HIV therapy

A
  • Reverse transcriptase (RT) inhibitors
    • nucleoside analogs (NRTIs)
    • non-nucleoside inhibitors (NNRTIs)
  • Protease inhibitors (PIs)
  • Fusion inhibitors
  • CCR5 antagonists
  • Integrase inhibitors
43
Q

NRTIs:

NNRTIs:

Protease Inhibitors:

Fusion Inhibitors:

CCR5 Antagonists:

Integrase Inhibitors:

A

NRTIs: Zidovudine; Lamivudine; Abacavir; Tenofovir; Emtricitabine

NNRTIs: Efavirenz

Protease Inhibitors: Lopinavir; Ritonavir (booster)

Fusion Inhibitors: Enfuvirtide

CCR5 Antagonists: Maraviroc

Integrase Inhibitors: Raltegravir

44
Q

Zidovudine (AZT) - First anti-HIV drug

Activation:

A
  • Thymidine nucleoside analog
  • Phosphorylated by cellular kinase (host cell)
  • AZT-trip inhibits RT and acts as chain terminator
45
Q

Zidovudine Side Effects

A
  • Bone marrow suppression
    • neutropenia, anemia
  • Avoid drugs which inhibit glucuronyl transferases (phase II)
  • Myopathy and myositis (after prolonged use)
46
Q

AZT and Inhibitors of Glucuronyl Transferases

A

Drugs that inhibit glucuronidation of AZT increase the hematologic toxicity of AZT

47
Q

Mechanism of other NRTIs

A
  • Specific chemistry differs, but general mechanism is analogous to AZT
    • Nucleoside analogs that must be phosphorylated to be active
    • Competitive inhibitors of RT
    • Cause DNA chain termination when incorporated into DNA
48
Q

Tenofovir Mechanism

Unlike AZT:

Similarity to AZT:

A

Unlike AZT: Nucleotide prodrug

Similarity to AZT: Inhibits RT by competinf for incorporation into DNA, causing chain termination

49
Q

Tenofovir

Uses:

Side Efects:

A

Uses: Combinatio therapy for HIV

Side Effects: Well tolerated - Some nausea/vomiting, diarrhea, flatulence

50
Q

Lamivudine (3TC) - for HIV treament

Synergism with AZT:

Admnistration:

Side Effects:

A

Synergism with AZT: Nucleoside analog inhibitor of RT

  • AZT resistant strains are 3TC sensitive and 3TC resistant strains are AZT-sensitive

Admnistration: 85% oral availability

Side Effects: Well tolerated - Nausea; diarrhea; rash

51
Q

Emtricitabine (fluorinated analog of ______)

Has same mechanism and resistance as ____

A

Lamivudine; 3TC

52
Q

Abacavir

Mechanism of Action:

Adverse effect:

A

Mechanism of Action: Nucleoside analog inhibitor of RT

Adverse effect: Hypersensitivity

  • Associated with HLA-B*5701 allele
  • If hypersensitivity occurs, stop drug immediately and never restart
53
Q

Other side effects associated with a number of NRTIs

A
  • Lactic acidosis
  • Hepatic steatosis (fatty liver)
  • Myopathy
  • Dilated cardiomyopathy
54
Q

Some differences between NRTIs and NNRTIs

A
  • Non-nucleoside inhibitors of RT
  • All are active as given; do not require phosphorylation to be active
  • Bind elsewhere on the enzyme
55
Q

Efavirenz

Categorization:

Uses:

Side Effects:

A

Categorization: NNRTI

Uses: Part of multi-drug therapy for HIV (#1 anti HIV drug in USA)

Side Effects:

  • Rash
  • CNS/psychiatric symptoms (various)
    • Nightmares, vivid dreams
    • 50% of patients, especially early in Tx
56
Q

Is Ritonavir a Protease Inhibitor (P.I)?

A

NO! it is used as a P.I booster, not as a P.I

57
Q

Use of Protease Inhibitors:

Mechanism of Protease Inhibitors

A

Use of Protease Inhibitors:

  • In combination with inhibitors of RT
  • Significantly decrease viral blood load

Mechanism of Protease Inhibitors

  • Prevents viral aspartic protease from cleaving Gag-pol polypeptide into separate functional proteins
  • Competitive inhibitor of protease active site
  • Results in non-infectious viral particles
58
Q

Toxicities common to a number of protease inhibitors (including Lopinavir)

A
  • Diabetes (insulin resistance)
  • Alterations in lipid metabolism
  • Fat redistribution
  • Alters metabolism of many other drugs (potent CYP3A inhibitors)
59
Q

Ritonavir Use:

A
  • Too toxic to dose as a protease inhibitor
  • Used to boost levels of other protease inhibitors because it blocks their metabolism by CYP3A
60
Q

Enfuvirtide

Class:

Use:

Advantage:

Mechanism of Action:

A

Class: Fusion inhibitors

Use: for HIV-1 only - experienced patients who have failed multiple regimens

Advantage: 2x daily injections

Mechanism of Action: Binds to gp41 subunit of HIV glycoprotein; blocks conformational change required for membrane fusion to CD4+ cells

61
Q

Enfuvirtide Side Effects

A
  • Local injection site reactions (98%)
  • Diarrhea, nausea, fatigue
  • Mainly used as a later option when other regimens have failed
62
Q

Maravirok

Class:

Use:

Mechanism of Action:

A

Class: CCR5 antagonist

Use: Treatment of CCR5-tropic HIV-1 - Effective in strains resistant to other drugs

Mechanism of Action: Antagonist of chemokine co-receptor CCR5, preventing interaction with HIV gp120

  • Blocks entry of HIV into cells
63
Q

Maraviroc side effects

A
  • Possible hepatotoxicity
  • Possible cardiovascular events
  • Most common
    • Cough, fever, rash, abdominal pain
64
Q

Raltegravir

Class:

Approved Use:

Mechanism:

A

Class: Integrase inhibitor

Approved Use: Treatment of HIV-1 in new and treatment experienced patients

  • Works on virus that is resistant to other drugs

Mechanism: Inhibits HIV-1 integrase activity preventing integration of HIV-1 DNA into the genome

65
Q

Raltegravir Side Effects:

A

Generally well-tolerated

66
Q

Current reasons for HIV therapeutic failure

A
  • Failure to maintain adherence to drug regimens (biggest issue)
  • Restistant strains emerge
67
Q

Drug combinations for treating HIV

HAART:

A

3 or more drugs per patient (2 or more drug classes)

HAART: Highly active anti-retroviral therapy

  • Combination of drugs of 2 or more classes
68
Q

DHHS guidelines: There should be urgency in initiating HAART therapy when CD4 count is < ____

A

350

69
Q

Occupational risk for HIV and initiation of anti-HIV drugs

A
  • Needlestick transmission (0.3%)
  • Initiate anti-HIV drugs ASAP
    • Even 24-36 hours may be too late

PDA Block 3 (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions